CA2978627A1 - Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance - Google Patents

Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance Download PDF

Info

Publication number
CA2978627A1
CA2978627A1 CA2978627A CA2978627A CA2978627A1 CA 2978627 A1 CA2978627 A1 CA 2978627A1 CA 2978627 A CA2978627 A CA 2978627A CA 2978627 A CA2978627 A CA 2978627A CA 2978627 A1 CA2978627 A1 CA 2978627A1
Authority
CA
Canada
Prior art keywords
thiazol
phenyl
trifluoromethanesulfonamide
chloro
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978627A
Other languages
English (en)
French (fr)
Inventor
Sebastian Bernales
Jeffrey Lindquist
Mausumee Guha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Technologies LLC
Original Assignee
Medivation Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies LLC filed Critical Medivation Technologies LLC
Publication of CA2978627A1 publication Critical patent/CA2978627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2978627A 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance Abandoned CA2978627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128251P 2015-03-04 2015-03-04
US62/128,251 2015-03-04
PCT/US2016/020644 WO2016141159A1 (en) 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance

Publications (1)

Publication Number Publication Date
CA2978627A1 true CA2978627A1 (en) 2016-09-09

Family

ID=55754401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978627A Abandoned CA2978627A1 (en) 2015-03-04 2016-03-03 Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance

Country Status (5)

Country Link
US (1) US10183015B2 (https=)
EP (1) EP3265088A1 (https=)
JP (1) JP2018507234A (https=)
CA (1) CA2978627A1 (https=)
WO (1) WO2016141159A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
EP3746070A4 (en) * 2018-01-29 2021-09-01 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A 6-LINKED CENTER RING
CA3127828A1 (en) * 2019-01-28 2020-08-06 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
WO2020191163A1 (en) * 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
WO2021097123A1 (en) * 2019-11-13 2021-05-20 Capulus Therapeutics, Llc Thiophene compounds with cyclic amides, and uses thereof
CN114945365A (zh) * 2019-11-13 2022-08-26 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring
EP4185584A1 (en) * 2020-07-24 2023-05-31 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
WO1999040088A1 (en) 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
EP1237875B1 (en) 1999-12-16 2005-08-31 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
TWI275589B (en) 2000-06-22 2007-03-11 Dow Agrosciences Llc 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006131336A1 (en) 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CA2609574A1 (en) 2005-06-09 2006-12-21 Schering-Plough Ltd. Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
JP5461197B2 (ja) * 2007-02-02 2014-04-02 ベイラー カレッジ オブ メディスン 代謝障害を処置するための組成物および方法
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
BRPI0808789A2 (pt) 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
AU2008340113B2 (en) 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2011085269A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
JP2014062047A (ja) 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
TW201332989A (zh) 2011-12-23 2013-08-16 Millennium Pharm Inc 雜芳基化合物及其用途
US20140364460A1 (en) 2012-01-18 2014-12-11 The Trustees Of Columbia University In The City Of New York USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
WO2014210389A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
SI3038622T1 (en) * 2013-08-28 2018-08-31 Medivation Technologies Llc Heterocyclic compounds and methods of use
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors

Also Published As

Publication number Publication date
JP2018507234A (ja) 2018-03-15
US10183015B2 (en) 2019-01-22
EP3265088A1 (en) 2018-01-10
WO2016141159A1 (en) 2016-09-09
US20180028518A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CA2978627A1 (en) Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
JP7037679B2 (ja) 新規の二環式ブロモドメイン阻害剤
EP3038622B1 (en) Heterocyclic compounds and methods of use
JP7288527B2 (ja) Ｐｒｃ２阻害剤
KR101345497B1 (ko) 설폰아미드 유도체
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
KR20240006606A (ko) Nav1.8 억제제로서의 아릴 3-옥소피페라진 카르복스아미드 및 헤테로아릴 3-옥소피페라진 카르복스아미드
AU2012345557A1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP2018514524A (ja) ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
CN101595105A (zh) 作为scd抑制剂的2-取代的5元杂环化合物
CA2922703A1 (en) Compositions and methods for the treatment of metabolic and body weight related disorders
MX2008015229A (es) Compuestos organicos.
CA2890699A1 (en) Combination therapy
EP1689389A2 (en) Indole compounds
JP2018507235A (ja) ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤
TW202039447A (zh) 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
KR20180095797A (ko) Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
TW202039486A (zh) 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
JP2025529797A (ja) 複素環ｒｂｍ３９モジュレーター
WO2019084681A1 (en) Methods of treating elevated plasma cholesterol
JP2025542413A (ja) プロテインチロシンキナーゼ阻害剤及びその医療上の使用
JP2022507958A (ja) 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
CA3115960A1 (en) Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
EP3893892A1 (en) Organic compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210903